LANNETT CO INC
LCI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LCI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2023.
Tracking 9 pipeline candidates · 28 FDA decisions for LANNETT CO INC.
Run LANNETT CO INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available LANNETT CO INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
43.4 months
OCF -$8M · Net income -$101M
Lead: Approved
9 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is LANNETT CO INC's lead drug candidate?
LANNETT CO INC's most advanced tracked candidate is biosimilar insulin aspart (Preclinical) for diabetes.
Who is the CEO of LANNETT CO INC?
Strategy The Board is the chief executive officer of LANNETT CO INC (LCI).
What therapeutic areas does LANNETT CO INC focus on?
LANNETT CO INC develops therapies across Oncology, Neurology, Metabolic, Respiratory, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.